BR112022001125A2 - Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos - Google Patents
Compostos macrocíclicos como agonistas de sting, seus métodos e seus usosInfo
- Publication number
- BR112022001125A2 BR112022001125A2 BR112022001125A BR112022001125A BR112022001125A2 BR 112022001125 A2 BR112022001125 A2 BR 112022001125A2 BR 112022001125 A BR112022001125 A BR 112022001125A BR 112022001125 A BR112022001125 A BR 112022001125A BR 112022001125 A2 BR112022001125 A2 BR 112022001125A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- macrocyclic compounds
- sting agonists
- compounds
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
compostos macrocíclicos como agonistas de sting, seus métodos e seus usos. são descritos compostos macrocíclicos tendo a fórmula geral (i) ou (ii), e suas formas tautoméricas, estereo-isômeros, sais farmaceuticamente aceitáveis, hidratos, solvatos e pró-fármacos dos mesmos, sua combinação com medicamentos adequados, processos correspondentes para a síntese, composições farmacêuticas, e usos dos compostos aqui descritos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029556 | 2019-07-22 | ||
| IN201921051086 | 2019-12-10 | ||
| IN202021003961 | 2020-01-29 | ||
| PCT/IB2020/056875 WO2021014365A1 (en) | 2019-07-22 | 2020-07-22 | Macrocyclic compounds as sting agonists and methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001125A2 true BR112022001125A2 (pt) | 2022-03-15 |
Family
ID=72422197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001125A BR112022001125A2 (pt) | 2019-07-22 | 2020-07-22 | Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20220289763A1 (pt) |
| EP (1) | EP4004002B1 (pt) |
| JP (1) | JP7592689B2 (pt) |
| KR (1) | KR20220035955A (pt) |
| CN (1) | CN114174303B (pt) |
| AU (1) | AU2020319058A1 (pt) |
| BR (1) | BR112022001125A2 (pt) |
| CA (1) | CA3147397A1 (pt) |
| CL (1) | CL2022000145A1 (pt) |
| CO (1) | CO2022001814A2 (pt) |
| CR (1) | CR20220029A (pt) |
| DK (1) | DK4004002T3 (pt) |
| EC (1) | ECSP22005485A (pt) |
| ES (1) | ES2989915T3 (pt) |
| FI (1) | FI4004002T3 (pt) |
| GE (1) | GEP20247627B (pt) |
| HR (1) | HRP20241222T1 (pt) |
| HU (1) | HUE068456T2 (pt) |
| IL (1) | IL289740B1 (pt) |
| LT (1) | LT4004002T (pt) |
| MA (1) | MA56674B1 (pt) |
| MX (1) | MX2022000939A (pt) |
| PE (1) | PE20220937A1 (pt) |
| PH (1) | PH12022550175A1 (pt) |
| PL (1) | PL4004002T3 (pt) |
| PT (1) | PT4004002T (pt) |
| RS (1) | RS66126B1 (pt) |
| SA (1) | SA522431429B1 (pt) |
| SI (1) | SI4004002T1 (pt) |
| SM (1) | SMT202400399T1 (pt) |
| UA (1) | UA129653C2 (pt) |
| WO (1) | WO2021014365A1 (pt) |
| ZA (1) | ZA202201375B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220056176A (ko) | 2019-08-02 | 2022-05-04 | 메르사나 테라퓨틱스, 인코포레이티드 | 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물 |
| EP4218826A3 (en) | 2020-04-02 | 2023-10-25 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising sting agonists |
| KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
| MX2023008327A (es) * | 2021-01-15 | 2023-08-22 | Seagen Inc | Anticuerpos inmunomoduladores de anticuerpo-farmaco. |
| EP4313962A4 (en) * | 2021-03-30 | 2025-02-26 | Jacobio Pharmaceuticals Co., Ltd. | Novel compounds useful as sting agonists and uses thereof |
| AU2023407213A1 (en) * | 2022-12-22 | 2025-07-03 | Aculeus Therapeutics Pty Ltd | Benzimidazole derivatives for the modulation of sting |
| WO2025012057A1 (en) * | 2023-07-07 | 2025-01-16 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| WO2025017045A1 (en) * | 2023-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
| CN119490423A (zh) * | 2023-08-15 | 2025-02-21 | 沈阳中化农药化工研发有限公司 | 一种制备2-氟-3-氨基苯甲酸及其酯类化合物的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| AR046959A1 (es) | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| WO2007044515A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| JP2009540013A (ja) | 2006-06-15 | 2009-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アニリノ−４−（複素環）アミノ−ピリミジン |
| WO2008090570A1 (en) | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Novel antimicrobials |
| TW201000447A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| EP2651926A4 (en) * | 2010-12-15 | 2014-07-09 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| US9540338B2 (en) | 2012-12-28 | 2017-01-10 | Nippon Zoki Pharmaceutical Co., Ltd. | Substituted cinnamic acid amides for treating pain |
| ES2692226T3 (es) * | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| MX387353B (es) | 2016-04-07 | 2025-03-18 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas. |
| MX2018012266A (es) | 2016-04-07 | 2019-05-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas como moduladores de proteinas. |
| JP7008064B2 (ja) | 2016-05-27 | 2022-01-25 | 杭州英創医薬科技有限公司 | Ｆｇｆｒ４阻害剤としてのヘテロ環式化合物 |
| EA036338B1 (ru) * | 2017-02-22 | 2020-10-28 | Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед | Гетероциклические амиды, пригодные в качестве модуляторов белков |
| JP2020524717A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの小分子調節因子 |
| PE20200696A1 (es) | 2017-06-22 | 2020-06-16 | Curadev Pharma Ltd | Moduladores de moleculas pequenas de sting humana |
| WO2018234807A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | HETEROCYCLIC MODULATORS WITH SMALL MOLECULES OF HUMAN STING |
| EP3658138B1 (en) | 2017-07-27 | 2023-04-19 | Stingray Therapeutics, Inc. | Substituted-3h-imidazo(4,5-c)pyridine and 1h-pyrrolo(2,3-c)pyridine series of novel ectonucleotide pyrophsphatase/phosphodiestrase-1 (enpp1) and stimulator for interferon genes (sting) modulator as cancer immunotherapeutics |
| MA49773A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b |
| EP3661498A4 (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | STING THIOPHENE BENZO [B] AGONISTS FOR CANCER TREATMENT |
| JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| EP3692033A1 (en) * | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| JP7530380B2 (ja) | 2019-03-28 | 2024-08-07 | ルピン・リミテッド | Ｓｔｉｎｇアゴニストとしての大環状化合物 |
-
2020
- 2020-07-22 EP EP20768090.1A patent/EP4004002B1/en active Active
- 2020-07-22 UA UAA202200745A patent/UA129653C2/uk unknown
- 2020-07-22 HR HRP20241222TT patent/HRP20241222T1/hr unknown
- 2020-07-22 AU AU2020319058A patent/AU2020319058A1/en active Pending
- 2020-07-22 CR CR20220029A patent/CR20220029A/es unknown
- 2020-07-22 KR KR1020227005943A patent/KR20220035955A/ko active Pending
- 2020-07-22 PE PE2022000120A patent/PE20220937A1/es unknown
- 2020-07-22 PL PL20768090.1T patent/PL4004002T3/pl unknown
- 2020-07-22 PH PH1/2022/550175A patent/PH12022550175A1/en unknown
- 2020-07-22 SI SI202030501T patent/SI4004002T1/sl unknown
- 2020-07-22 CN CN202080053237.XA patent/CN114174303B/zh active Active
- 2020-07-22 DK DK20768090.1T patent/DK4004002T3/da active
- 2020-07-22 MX MX2022000939A patent/MX2022000939A/es unknown
- 2020-07-22 IL IL289740A patent/IL289740B1/en unknown
- 2020-07-22 ES ES20768090T patent/ES2989915T3/es active Active
- 2020-07-22 FI FIEP20768090.1T patent/FI4004002T3/fi active
- 2020-07-22 BR BR112022001125A patent/BR112022001125A2/pt unknown
- 2020-07-22 MA MA56674A patent/MA56674B1/fr unknown
- 2020-07-22 WO PCT/IB2020/056875 patent/WO2021014365A1/en active IP Right Grant
- 2020-07-22 SM SM20240399T patent/SMT202400399T1/it unknown
- 2020-07-22 JP JP2022504707A patent/JP7592689B2/ja active Active
- 2020-07-22 PT PT207680901T patent/PT4004002T/pt unknown
- 2020-07-22 CA CA3147397A patent/CA3147397A1/en active Pending
- 2020-07-22 RS RS20241052A patent/RS66126B1/sr unknown
- 2020-07-22 US US17/628,619 patent/US20220289763A1/en active Pending
- 2020-07-22 HU HUE20768090A patent/HUE068456T2/hu unknown
- 2020-07-22 LT LTEPPCT/IB2020/056875T patent/LT4004002T/lt unknown
- 2020-07-22 GE GEAP202015883A patent/GEP20247627B/en unknown
-
2022
- 2022-01-19 SA SA522431429A patent/SA522431429B1/ar unknown
- 2022-01-21 EC ECSENADI20225485A patent/ECSP22005485A/es unknown
- 2022-01-21 CL CL2022000145A patent/CL2022000145A1/es unknown
- 2022-01-28 ZA ZA2022/01375A patent/ZA202201375B/en unknown
- 2022-02-21 CO CONC2022/0001814A patent/CO2022001814A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001125A2 (pt) | Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos | |
| BR112022008375A2 (pt) | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| BR112021018947A2 (pt) | Compostos macrocíclicos como agonistas de sting | |
| CY1124652T1 (el) | Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| CR20220234A (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
| BR112021022659A2 (pt) | Compostos triarílicos para o tratamento de doenças pd-l1 | |
| CA3057882A1 (en) | Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein | |
| PH12020550792A1 (en) | Compounds useful for inhibiting cdk7 | |
| MX2023013096A (es) | Uso farmaceutico de compuesto de peptidos ciclicos. | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| MX390625B (es) | Inhibidores selectivos de jak1. | |
| MX2021005050A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| CO2021006482A2 (es) | Ureas cíclicas | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| PH12020550253A1 (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| MX2021010869A (es) | Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| EA202191051A1 (ru) | Ингибитор аврора-киназы a для применения для лечения нейробластомы | |
| MX2021011376A (es) | Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. |